Technology Appraisal Committee Meeting (Committee C)

### Minutes: Confirmed

### Date and Time: Tuesday 7 July 2020 at 9:30am (Held via Zoom)

### Committee Members Present:

* **Chair** Stephen O’Brien Present for all notes
* Alex Cale Present for notes 1 to 6
* Michael Chambers Present for all notes
* Prithwiraj Das Present for all notes
* Rob Forsyth Present for all notes
* David Foreman Present for all notes
* Nigel Langford Present for all notes
* Andrea Manca Present for all notes
* Iain McGowan Present for all notes
* Kirandip Moyo Present for all notes
* Mudasar Mushtaq Present for all notes
* Richard Nicholas Present for all notes
* Ugochinyere Nwulu Present for notes 7 to 15
* Stella O'Brien Present for all notes
* Subhash Pokhrel Present for all notes
* Andrew Renehan Present for all notes
* Matthew Stevenson Present for all notes
* Paul Tappenden Present for all notes

### NICE Staff Present:

* Joanne Holden, Associate Director, Present for notes 1 to 6
* Linda Landalls, Associate Director, Present for notes 7 to 15
* Louise Jafferally, Project Manager, Present for all notes
* Mandy Brereton, Assistant Project Manager, Present for all notes
* Gemma Smith, Coordinator, Present for all notes
* Anita Sanga, Technical Analyst, Present for notes 1 to 6
* Sally Doss, Technical Adviser, Present for notes 1 to 6
* Emma Douch, Technical Analyst, Present for notes 7 to 15
* Christian Griffiths, Technical Adviser, Present for notes 7 to 15
* Mandy Tonkinson, Public Involvement Advisor, Present for notes 1 to 2.8
* Heidi Livingstone, Public involvement Advisor, Present for notes 7 to 11
* Catherine Pank, Coordinator, Meetings in Public, Present for notes 1 to 2.8 & 7 to 11

### Evidence Review Groups:

* Tracey Jhita, Evidence Review Group, Present for notes 1 to 2.8
* Samantha Barton, Evidence Review Group, Present for notes 1 to 2.8
* Steve Edwards. Evidence Review Group, Present for notes 1 to 2.8
* Jonathan Shepherd, Evidence Review Group, Present for notes 7 to 11
* Keith Cooper, Evidence Review Group, Present for notes 7 to 11
* Olu Onyimadu, Evidence Review Group, Present for notes 7 to 11

### Clinical & Patient Experts:

* Karthik Ramasamy, Clinical Expert, Present for notes 1 to 2.8
* Balaji Venugopal, Clinical Expert, Present for notes 7 to 11
* Tom Waddell, Clinical Expert, Present for notes 7 to 11
* Shelagh McKinlay, Patient Expert, Present for notes 1 to 2.8
* Franko Kowalczuk, Patient Expert, Present for notes 1 to 2.8
* Susanna Smith, Patient Expert, Present for notes 7 to 11
* Michael Lee, Patient Expert, Present for notes 7 to 11
* Professor Peter Clark, Cancer Drugs Fund Clinical Lead, Present for notes 1 to 6
* Steve Williamson, NHS Commissioning Lead, Present for notes 7 to 15

### Other non-public attendees:

* Zain Hussain, NICE Observer, Present for all notes
* Fatima Chunara, NICE Observer, Present for all notes
* Rebecca Thomas, NICE Observer, Present for all notes
* Aminata Thiam, NICE Observer, Present for all notes
* Ross Wilkinson, NICE Observer, Present for all notes
* Victoria Kelly, NICE Observer, Present for notes 7 to 15
* Edgar Masanga, NICE Observer, Present for all notes
* Ria Skelton, NICE Observer, Present for notes 1 to 6
* Sarah Bromley, NICE Observer, Present for notes 7 to 15
* Rebecca Boffa, NICE Observer, Present for notes 1 to 2.8 & 7 to 11
* Anne Oyewole, NICE Observer, Present for notes 1 to 2.8 & 7 to 11
* Alex Inskip, NICE Observer, Present for notes 1to 2.8 & 7 to 11
* Carrie Gardner, NICE Observer, Present for all notes 1 to 6

### Notes

### Appraisal of Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy [ID1493]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) and representatives from Amgen.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

	1. Prithwiraj Das declared a non-financial and personal interest as he works at Boehringer Ingelheim Ltd as Market Access Lead in Specialty Medicines (Oncology, Inflammation, Lytics). He also declared he has not worked on any of the indications under investigation in the last 12 months.
		1. It was agreed that this declaration **would not** prevent Prithwiraj from participating on this topic.
	2. Matthew Stevenson declared a financial interest and noted he was conflicted for TA457 as he had given advice to the previous company who made carfilzomib directly related to this topic.
		1. It was agreed that this declaration **would not** prevent Matthew from participating on this topic.
	3. Andrea Manca declared non-financial and personal interest as he is a co-investigator in a NIHR PGfAR grant in multiple myeloma.
		1. It was agreed that this declaration **would not** prevent Andrea from participating on this topic.
	4. Karthik Ramasamy declared direct & indirect interests as he has attended advisory boards for Amgen, received lecture fees from Amgen and his employer has received a trial grant from Amgen.
		1. It was agreed that this declaration **would not** prevent Karthik from participating on this topic.
	5. Shelagh McKinlay declared indirect interests as Myeloma UK received funding from Amgen.
		1. It was agreed that this declaration **would not** prevent Shelagh from participating on this topic.
	6. No further conflicts of interest were declared for this appraisal.
	7. The Chair introduced the lead team who gave presentations on the clinical and cost effectiveness of the treatment.
	8. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

**Part 2– Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)**

1. The committee discussed confidential information submitted as part of this appraisal.
2. Agreement on the content of the Appraisal Consultation Document (ACD).
3. The committee decision was based on consensus.
4. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions

### Appraisal of Pembrolizumab with axitinib for untreated advanced renal cell carcinoma [ID1426]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from MSD.
2. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests

	1. Prithwiraj Das declared non-financial and personal interest. As he works at as he works at Boehringer Ingelheim Ltd as Market Access Lead in Specialty Medicines (Oncology, Inflammation, Lytics). He also declared he has not worked on any of the indications under investigation in the last 12 months.
		1. It was agreed that this declaration **would not** prevent Prithwiraj from participating on this topic.
	2. Susanna Smith declared indirect interests as Kidney Cancer UK receives funding from numerous companies.
		1. It was agreed that this declaration **would not** prevent Susanna from participating on this topic.
	3. Balaji Venugopal declared direct financial & non-financial interests as he is on advisory boards for Bristol Myers Squibb (BMS), EUSA pharma, Merck, Merck Sharp and Dohme (MSD) and is a Principal investigator for clinical trials sponsored by MSD, Ipsen and Pfizer
		1. It was agreed that this declaration **would not** prevent Balaji from participating on this topic.
	4. Tom Waddell declared indirect interests as he is a clinical advisor to the LRiG ERG review of company submission for competitor combination (Avelumab and Axitinib) and received a research grant from MSD.
		1. It was agreed that this declaration **would not** prevent Tom from participating on this topic.
3. No further conflicts of interest were declared for this appraisal.
4. The Chair introduced the presentations on the clinical and cost effectiveness of the treatment.
5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy

**Part 2 – Closed session (company representatives, clinical and patient experts, ERG, and members of the public were asked to leave the meeting)**

1. The committee discussed confidential information submitted as part of this appraisal.
2. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
3. The committee decision was based on consensus.
4. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.